This study shows that the anti-CD38 #antibody #CM313 is well tolerated in #SystemicLupusErythematosus & delivers dose-dependent benefits, reduced #autoantibodies, and improved complement levels, supporting further clinical development.

#FeaturedArticle #STTT: doi.org/10.1038/s413...

Timberlyne Therapeutics Secures $180 Million for Game-Changing Monoclonal Antibody CM313 Timberlyne Therapeutics has closed a $180 million Series A financing round to promote CM313, a novel anti-CD38 monoclonal antibody designed to tackle severe autoimmune diseases.

Timberlyne Therapeutics Secures $180 Million for Game-Changing Monoclonal Antibody CM313 #United_States #San_Diego #Keymed_Biosciences #CM313 #Timberlyne